查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609961

乙酰胺酚静脉注射液市场规模、份额、趋势分析报告：按适应症、应用、最终用途、地区和细分市场预测，2025-2030 年

Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

乙酰胺酚静脉注射市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球乙酰胺酚静脉注射液市场规模将达到9.9423亿美元，2025-2030年复合年增长率为3.43%。

需要疼痛管理的慢性疾病盛行率的上升预计将在预测期内推动该行业的成长。越来越多地使用对乙酰胺酚来减少阿片类药物对疼痛治疗的依赖，预计将加速静脉注射乙酰胺酚的需求成长。静脉注射乙酰胺酚是一种稳定的对乙酰胺酚製剂，用于治疗轻度至中度疼痛。乙酰胺酚不会抑制血小板功能，因此比其他非类固醇消炎剂更常用于治疗有消化性溃疡或气喘病史的患者。

随着抱怨术后疼痛的患者数量增加，对副作用较少的药物和产品的需求预计将会增加。 《国际外科杂誌》发表的论文显示，2022年3月，美国77%至83%的患者、泰国80%的患者、瑞典76%的患者、德国29.5%的患者将接受手术。报告说有严重到中度的背痛。静脉注射乙酰胺酚用于治疗术后急性疼痛以及在整形外科、牙科、妇科等手术中使用。由于手术数量的增加和术后疼痛患者的增加，预计未来几年对该产品的需求将会很高。然而，多种非专利药的上市预计将在预测期内阻碍该行业的发展。

例如，2020年12月，山德士国际有限公司在美国推出了对乙酰胺酚注射液的学名药。本产品将以 10 mg/mL 的浓度装在 100 mL管瓶中，与鸦片类止痛药合併用于治疗儿科病患的轻度至中度病症。世界各地各行业的主要企业正在采取各种策略倡议来扩大业务并获得相对于其他公司的竞争优势。例如，2021 年 12 月，Leucadia Pharmaceuticals 推出并宣布了对乙酰胺酚注射液，这是 FDA核准的对乙酰胺酚注射液的非专利药，由 Mallinckrodt Pharmaceuticals 生产。

乙酰胺酚静脉注射市场报告亮点

  • 从应用来看，预计 2025 年至 2030 年，供热领域的复合年增长率最快。
  • 这一领域的成长归因于乙酰胺酚静脉注射的快速起效和有效性。
  • 2024年，由于静脉注射乙酰胺酚用于治疗术后疼痛和快速退烧的使用量增加，外科应用领域占据了最大的销售份额。
  • 由于产品使用量高，以减少经济对用于疼痛管理的鸦片类药物的依赖，北美将在 2024 年主导全球产业。
  • 公司专注于地域扩张，采取联盟、伙伴关係、新产品发布和策略倡议等策略来维持行业竞争力。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章乙酰胺酚静脉注射市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 乙酰胺酚静脉注射液市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章乙酰胺酚静脉注射液市场：适应症估计及趋势分析

  • 细分仪表板
  • 乙酰胺酚静脉注射液市场：适应症变化分析
  • 乙酰胺酚静脉注射液按适应症的市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 疼痛
  • 发烧

第五章乙酰胺酚静脉注射液市场：应用估算及趋势分析

  • 细分仪表板
  • 乙酰胺酚静脉注射液市场：应用变化分析
  • 乙酰胺酚静脉注射液市场－依应用前景
  • 2018-2030年市场规模、预测及趋势分析
  • 外科手术
  • 非手术手术

第六章乙酰胺酚静脉注射市场：最终用途估计与趋势分析

  • 细分仪表板
  • 乙酰胺酚静脉注射液市场：最终用途变化分析
  • 依最终用途分類的乙酰胺酚静脉注射液市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院
  • 诊所
  • 其他的

第七章乙酰胺酚静脉注射市场：区域估计及趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 2024 年企业市场占有率分析
  • 主要企业简介
    • Mallinckrodt（Mallinckrodt Pharmaceuticals）
    • Cipla Inc.
    • Lupin
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Abbott
    • Sanofi
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68039-965-3

Paracetamol IV Market Growth & Trends:

The global paracetamol IV market size is estimated to reach USD 994.23 million by 2030, expanding at a CAGR of 3.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic disorders that requires pain management is expected to facilitate the growth of the industry during the forecast period. The enhanced usage of acetaminophen to reduce the dependence on opioids for pain management is projected to accelerate the growth in demand for paracetamol IV. The IV paracetamol is a stable acetaminophen form and is intended for mild to moderate pain management. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma, as it lacks interference with the function of platelets.

Rising cases of patients reporting postoperative pain are expected to propel the demand for drugs and products with fewer side effects. As per the article published in the International Journal of Surgery, in March 2022, 77% - 83% of patients in the U.S., 80% of patients in Thailand, 76% of patients in Sweden, and 29.5% of patients in Germany reported severe to moderate postoperative pain. The IV paracetamol is intended for usage in the treatment of acute postoperative pain and during the surgeries, such as orthopedic, dental, and gynecological. A rise in the number of surgeries performed and patients experiencing post-operative pain is expected to create a high product demand in the years to come. However, the availability of multiple generic products is expected to hinder the industry during the forecast period.

For instance, in December 2020, Sandoz International GmbH launched a generic acetaminophen injection in the U.S. The product will be available in 10 mg/mL concentration, in a 100 mL vial for the treatment of mild to moderate in conjunction with opioid analgesics for pediatric patients. Key players operating in the global industry are following various strategic initiatives for business expansion and to gain a competitive edge over others. For instance, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of a generic acetaminophen injection, which is an FDA-approved generic that corresponds to the acetaminophen injection manufactured by Mallinckrodt Pharmaceuticals.

Paracetamol IV Market Report Highlights:

  • Based on application, the pyrexia segment is estimated to register the fastest CAGR from 2025 to 2030.
  • The growth of the segment is attributed to the rapid action & effectiveness of paracetamol being administered intravenously.
  • The surgical application segment held the largest revenue share in 2024 due to the increased usage of paracetamol IV for the treatment of post-operative pain and rapid relief from fever.
  • North America dominated the global industry in 2024 owing to high product usage for reducing the dependence of the economy on opioids for the management of pain.
  • Companies are focusing on geographical expansion by adopting strategies, such as collaborations, partnerships, new product launches, and strategic initiatives to maintain a competitive position in the industry.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Paracetamol IV Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising cases of postoperative pain
      • 3.2.1.2. Increasing prevalence of chronic disorders
      • 3.2.1.3. Increasing use of intravenous paracetamol in combination with NSAIDs and narcotics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Overdose of paracetamol IV
      • 3.2.2.2. Availability of generic products
  • 3.3. Paracetamol IV Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Paracetamol IV Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Paracetamol IV Market: Indication Movement Analysis
  • 4.3. Paracetamol IV Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Pain
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Pyrexia (Fever)
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Paracetamol IV Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Paracetamol IV Market: Application Movement Analysis
  • 5.3. Paracetamol IV Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Surgical
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-surgical
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Paracetamol IV Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Paracetamol IV Market: End Use Movement Analysis
  • 6.3. Paracetamol IV Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Clinics
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Paracetamol IV Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cipla Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lupin
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Dr. Reddy's Laboratories Ltd.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Aurobindo Pharma
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Sun Pharmaceutical Industries Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Novartis AG
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Pfizer, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Abbott
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Sanofi
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Bristol-Myers Squibb Company
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Paracetamol IV Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 Global Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 8 North America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 10 North America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 North America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 14 U.S. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 15 Canada Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 19 Mexico Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Mexico Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 21 Europe Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 23 Europe Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Europe Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 25 U.K. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 26 U.K. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 27 U.K. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 28 Germany Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Germany Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 30 Germany America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 31 France Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 32 France Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 33 France Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 34 Spain Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 35 Spain Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 37 Italy Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 38 Italy Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 39 Italy Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 42 Denmark Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 44 Sweden Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 45 Sweden Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 46 Norway Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 47 Norway Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 53 China Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 54 China Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 55 China Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 56 Japan Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 57 Japan Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 58 Japan Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 59 India Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 60 India Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 India Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 63 South Korea Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 64 South Korea Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 65 Australia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 66 Australia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 67 Australia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 69 Thailand Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 70 Thailand Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 73 Latin America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 74 Latin America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 76 Brazil Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Brazil Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 79 Argentina Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 80 Argentina Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 81 MEA Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 83 MEA Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 84 MEA Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 86 South Africa Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 87 South Africa Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 88 UAE Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 89 UAE Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 UAE Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Paracetamol IV market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Global Paracetamol IV market: Indication outlook and key takeaways
  • Fig. 10 Global Paracetamol IV market: Indication movement analysis
  • Fig. 11 Pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 12 Pyrexia (Fever) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Global Paracetamol IV market: Application type outlook and key takeaways
  • Fig. 14 Global Paracetamol IV market: Application type movement analysis
  • Fig. 15 Surgical market estimates and forecast, 2018 - 2030
  • Fig. 16 Non-Surgical market estimates and forecast, 2018 - 2030
  • Fig. 17 Global Paracetamol IV market: End use outlook and key takeaways
  • Fig. 18 Global Paracetamol IV market: End use movement analysis
  • Fig. 19 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 North America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging company's/disruptors/innovators